Analyse Black Diamond Therapeutics, Inc. (BDTX) — Kairos Score 62/100

À propos de Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Informations clés

🕴️ Activité des initiés (90 jours)

2 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Black Diamond Therapeutics, Inc..

🏦 Hedge Funds

15 fonds institutionnels déclarent une position sur BDTX dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur BDTX.

• Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
• Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.